Zynerba Pharma’s (NASDAQ:ZYNE) Zygel was granted FDA orphan drug designation for the treatment of 22q11.2 deletion syndrome. Also known as DiGeorge syndrome, 22q11.2 deletion syndrome is caused by a deletion of a small...
Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported positive topline data from its Phase 2 trial of Zygel for the treatment of autism spectrum disorder (ASD). Zygel is a cannabidiol-based gel that provides controlled...
Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported positive topline efficacy results, along with safety profile issues, from its open label Phase 2 study assessing the safety and efficacy of Zygel in developmental and...
The FDA granted Zynerba Pharma’s (NASDAQ:ZYNE) Zygel fast track designation for behavioral symptoms associated with Fragile X syndrome. Fragile X syndrome, a rare genetic condition caused by a mutation in the X...
Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated a Phase 2 trial to assess the safety, tolerability and efficacy of Zygel for the treatment of autism spectrum disorder (ASD). Zygel in a cannabidiol-based gel that...